1111 KANE CONCOURSE, BAY HARBOR ISLANDS, FL
Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Financial Results, Press Release
Other Events, Press Release
Subsidiary Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Material disclosure
Announce FDA Acceptance of CUTX-101 NDA Resubmission
Other Events
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Prospectus filed pursuant to Rule 424(b)(7)
Post-Effective Amendment to Registration Statement